Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
small decrease » small increased (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
small decrease » small increased (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
161
Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
-
162
Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
-
163
Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
-
164
Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
-
165
Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
-
166
Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
-
167
Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
-
168
Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
-
169
Table 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
-
170
Image 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
-
171
Image 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
-
172
Table 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
-
173
Image 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
-
174
Data Sheet 1_Dual upregulation of miRNA-143 and miRNA-506 in non-small cell lung cancer inhibits proliferation, motility, migration, and tumor growth.pdf
Published 2025“…Our work here evaluates the stable deregulation of two miRs, miR-143-3p, and miR-506-3p, individually and in combination, to elucidate their roles upon prolonged exposure in non-small cell lung cancer (NSCLC) cell lines. Following stable transductions using lentiviruses in A549 and H1975 cells, we evaluated cell cycle distribution, proliferation, migration, and in vivo tumor growth. …”
-
175
Data Sheet 1_The small GTPases FoRab5, FoRab7, and FoRab8 regulate vesicle transport to modulate vegetative development and pathogenicity in Fusarium oxysporum f. sp. conglutinans....
Published 2025“…There was a significant decrease in the activity of laccase, glucoamylase, and cellulase. …”
-
176
Table 1_The RNA-binding protein ProQ directly binds and regulates virulence genes in enterohemorrhagic Escherichia coli O157:H7.docx
Published 2025“…We found that deletion of proQ significantly enhanced cell adherence ability of EHEC and led to upregulation of the locus of enterocyte effacement (LEE) pathogenicity island. …”
-
177
DataSheet1_Genetic variants of LRRC8C, OAS2, and CCL25 in the T cell exhaustion-related genes are associated with non-small cell lung cancer survival.doc
Published 2024“…Background<p>T cell exhaustion is a state in which T cells become dysfunctional and is associated with a decreased efficacy of immune checkpoint inhibitors. …”
-
178
Data Sheet 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and...
Published 2024“…Introduction<p>Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. …”
-
179
Table 4_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel...
Published 2024“…Introduction<p>Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. …”
-
180
Table 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel...
Published 2024“…Introduction<p>Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. …”